AIR-DOCTOR
31.5.2022 12:02:03 CEST | Business Wire | Press release
Medical care and travel startup Air Doctor has secured $20M in funding for scaling the company globally. This second round of investment capitalizes on the worldwide influx in travelers after the Covid-19 pandemic and will enable the company to enter its next phase of growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531005013/en/
Air Doctor, raised $20 million, led by Lightspeed Venture Partners. Joining this round are Vintage Investment Partners and Munich Re Ventures, alongside The Phoenix , one of Israel's leading insurance providers, as well as Kamet Ventures , which led the company’s previous round.
Founded by Jenny Cohen Derfler, Efrat Sagi Ofir, Yam Derfler and Yegor Kurbachev, Air Doctor has previously raised $10.9 million since its launch in 2018. The startup currently employs over 60 people based in Israel and Europe.
The Air Doctor platform connects travelers who fall ill abroad with local private doctors through an easy-to-use mobile and web app. Air Doctor’s outpatient medical network covers 74 countries and includes over 20,000 medical professionals who provide either in-person or telemedicine consultations. Following the Covid-19 pandemic, medical assistance while traveling has become a major concern for travelers and insurers alike. Air Doctor’s platform provides the assurance travelers need to enjoy their trip.
In addition to bringing on board more developers to work on product customization, Air Doctor will use the new investment to hire new employees and open additional offices internationally. The company also has plans to expand the product and marketing teams, and the vetted medical professional network, particularly in the US and Europe.
In 2020, the COVID-19 outbreak brought the world to a standstill, with unprecedented and unanticipated consequences affecting people's lives and global economies. The travel and tourism sector experienced a severe economic slowdown as a result of stringent quarantine regulations and travel restrictions.
“As the world emerges from COVID-19, people have resumed travel, with a greater demand for suitable travel insurance and digital solutions. The pandemic has forced the industry to reassess local medical treatment available for travelers. Today, travelers testing positive for the Coronavirus will be able to seek medical care in the local communities they are in rather than in hospitals.” said Jenny Cohen Derfler, CEO and Founder of Air Doctor. “Air Doctor has become one of the fastest-growing startups, with tens of thousands registered users and many more accessing the network worldwide. Today the company offers a unique and distinctive digital product with almost no competition worldwide.” Said CEO Cohen Derfler
According to the World Economic Forum’s recent survey , the travel industry is expected to fully recover by 2024. Additionally, many countries may mandate travel insurance coverage. These two factors will create a dramatic surge in the need for better travel insurance. Furthermore, insurers facing travelers’ demands are seeking to expand their offer of digital, physical and online healthcare coverage to provide an improved customer experience and reduce claim costs.
“Building our partner and investor network will be an ongoing endeavor, as well as boosting our R&D capabilities and end-user activation. We’re also on the lookout to find new team members who are keen to join an exciting startup that is expanding globally,” said Efrat Sagi-Ofir, Co-Founder and Chief Revenue Officer of Air Doctor.
“Air Doctor addresses a major pain point for the health and travel insurance industry, and Lightspeed is excited to lead the company’s new $20 million funding round. Air Doctor continues to prove itself as an innovator in travel health by digitizing a significant aspect of the travel experience,” said Yoni Cheifetz, Partner at Lightspeed. “
About Air Doctor
Launched in Israel in 2018, Air Doctor is a startup that connects travelers seeking medical attention with local doctors whilst abroad through their intuitive mobile and desktop app. With a global network of over 20,000 medical professionals across 2,000 cities in 74 countries, Air Doctor provides travelers with peace of mind and aims to make healthcare accessible to everyone, everywhere.
About Lightspeed
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400 companies globally, including Snap, Nest, Nutanix, AppDynamics, MuleSoft, OYO, Guardant, Affirm, and GrubHub. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia, and Europe. www.lsvp.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
